FDA Drafts a Path to One BLA Per Gene-Editing Family

FDA's Center for Biologics Evaluation and Research has published draft guidance that would let a sponsor file one Biologics License Application covering an entire family of individualized, patient-specific genome-editing products — and add newly designed variants to that same license after approval using laboratory data bridged to the original clinical trial, rather than running a new trial for each one. The notice of availability for “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management” ran in the Federal Register on 28 October 2026, under Docket No. FDA-2026-D-11783; comments are due by 27 November.

Why one BLA per patient was never going to scale

Individualized genome-editing products — sometimes called n-of-1 or patient-specific therapies — are built to correct one patient's or a small group's exact genetic mutation, which means a program can generate a new molecular variant for nearly every patient it treats. Filing a complete, standalone BLA for each variant, the pathway CBER says sponsors have generally had to use, does not scale once a program moves past a handful of patients. Andrew Byrnes, Director of CBER's Division of Gene Therapy 1, is quoted by trade press describing the existing one-BLA-per-variant approach as infeasible and not necessary — language that signals the agency sees this as a structural bottleneck for an entire emerging product category, not a one-off accommodation for a single sponsor.

The mechanism: one license, a defined family, a lab-data bridge

The draft guidance's core proposal is a single BLA that covers a defined family of individualized variants rather than one product. For adding a new variant after that BLA is already licensed, the guidance describes a pathway built on in vitro — laboratory, not clinical — safety and potency data, bridged back to the clinical data that supported the original approval of the product family. In practice, that means a sponsor could justify a new patient-specific variant's safety and likely efficacy by showing it behaves comparably, on defined laboratory assays, to the variants already proven safe and effective in the clinic, instead of enrolling every new variant in its own clinical trial — a step that is often not feasible for a therapy custom-built for one patient in the first place.

What else is in scope

The guidance is not limited to the BLA-structure question. It also addresses manufacturing process validation for individualized products — relevant given that each variant may require its own manufacturing run rather than a standardized batch process — along with conventions for labeling and indication statements, and drug naming and identification practices suited to a product family whose individual members are, by design, each unique. It builds on two earlier 2026 draft guidances from CBER on genome-editing safety: an April 2026 draft on next-generation-sequencing safety assessment, and a June 2026 draft on leveraging prior knowledge in gene-therapy development. Read together, the three documents trace a consistent agency position: that an individualized therapy's safety case can lean more heavily on structured prior data and analytical bridging, and less on repeating a full clinical and regulatory package for every new patient-specific product.

What this changes for sponsors now

• Reassess BLA strategy for individualized or n-of-1 programs: a single-BLA, product-family structure may now be achievable instead of parallel standalone filings.
• Build the postapproval variant-addition package early. The guidance signals FDA will accept in vitro comparability and potency bridging data in lieu of new trials, which means sponsors should design their analytical bridging assays with that pathway in mind from the start, not retrofit them later.
• Route it to CMC and manufacturing-validation teams, not just clinical and regulatory. Process validation for variant-to-variant manufacturing is explicitly in scope.
• The comment window closes 27 November 2026. Sponsors with active individualized-product programs have roughly a month to flag labeling, naming or bridging-data provisions that do not fit their own product family before the guidance is finalized.

Frequently asked questions

What did FDA publish, and when?

A draft guidance titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management," from the Center for Biologics Evaluation and Research's Office of Therapeutic Products. The notice of availability published in the Federal Register on 28 October 2026, under Docket No. FDA-2026-D-11783, with comments due by 27 November 2026.

What problem is the guidance trying to solve?

Individualized, or patient-specific, genome-editing products are typically each a distinct variant built to correct one patient's or one small group's specific genetic mutation. Under current practice, sponsors have generally had to file a separate BLA for each variant. CBER's Andrew Byrnes, Director of the Division of Gene Therapy 1, is quoted calling that one-BLA-per-variant approach infeasible and unnecessary at the scale individualized therapies are reaching.

What does the draft guidance propose instead?

A single BLA covering multiple variants within a defined product family, plus a postapproval pathway for adding new patient-specific variants to an already-licensed BLA using in vitro (laboratory) safety and potency data bridged to the clinical data that supported the original approval — rather than requiring a new clinical trial for every new variant.

Is this guidance final or binding?

No. It is a draft guidance, non-binding, open for public comment through 27 November 2026. FDA guidance documents describe the agency's current thinking; sponsors may propose an alternative approach if it satisfies the applicable statutory and regulatory requirements.